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Abstract
Background: Menstrual blood-derived stromal/stem cells (MenSCs) are a new
population of refreshing and highly proliferative stem cells. Immunomodulatory effects
of MenSCs profoundly depend on their relative density.
Objective: To find whether MenSCs cultured at varying numbers would differentially
affect the allogenic peripheral blood mononuclear cells (PBMCs) key features.
Materials and Methods: PBMCs were co-cultured with various MenSCs numbers.
PBMCs proliferation was investigated via 3H-thymidine incorporation. Flow cytometry
was used to assess human leukocyte antigen (HLA)-DR, HLA-ABC, HLA-G, and co-
stimulatorymarkers onMenSCs and the percentage of regulatory T cells (Tregs) among
PBMCs. The concentration of cytokines was determined in supernatant of co-cultures.
Results: The support of PBMCs proliferation at low MenSCs densities correlated
with higher levels of pro-inflammatory interferon gamma (IFN-γ) in MenSCs/PBMCs
co-culture and increased expression of HLA-DR by MenSCs. On the other hand,
the suppressive property of MenSCs at higher densities was independent of Treg
frequency, but correlated with a high concentration of Interleukin (IL)-6 and IL-10 in
the co-cultures.
Conclusion: Totally, at different seeding densities, MenSCs could differentially interact
with PBMCs leading to significant changes in the level of anti- and/or pro-inflammatory
factors. These preliminary in vitro results are suggested to be taken into consideration
in experimental models of MenSC-based immunomodulation. Nonetheless, for efficient
utilization of MenSCs anti-inflammatory features in pre-clinical disease models, we still
need to broaden our knowledge on MenSC-immune system cross-talk; this could play
a part in designing more optimized MenSCs injection modalities in the case of future
pre-clinical and subsequently clinical settings.
Key words: Menstrual, Stromal cells, T cell response, Interferon-𝛾 , Regulatory T cells,
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1. Introduction
Mesenchymal stem cells (MSCs) can be
recovered from different sources (1) and have been
proposed to be beneficial for the treatment of such
immunological complications as transplantation-
induced graft versus host disease (GVHD) (2).
Immunomodulation is the principle feature of
almost all types of MSCs (3); indeed, MSCs
have been demonstrated to suppress mixed
lymphocyte reaction (MLR) (4), induce regulatory
T cell (Treg) generation, and decrease T helper
(Th)1 and Th17 differentiation (3, 5). However,
MSC clinical utilization has been reported to be
troublesome due to rather difficult and invasive
accessibility and also limited proliferative capacity
compared to certain stem cell subsets (6). As
a comparatively novel and promising stem cell
source, menstrual blood (MB) is a refreshing
and easy-to-access MSC source; such cells have
a high proliferation rate (7) and the capacity
to self-renew and differentiate into cells of all
three germ layers (8). In addition, regarding their
immunophenotype, menstrual blood-derived
stromal/stem cells (MenSCs) have been shown to
share quite similar features with their conventional
MSC counterparts (9).
However, data regarding MenSCs potential
interaction with immune cells is scarce. In
one study, MenSCs could suppress cellular
proliferation in allogeneic MLR, hinder IFN-γ
and TNF-α production, and stimulate Interleukin
(IL)-4 generation (10); this was the first work
suggesting MenSCs to share T cell inhibitory
functions with conventional MSCs. We further
demonstrated that, depending on their relative
frequency, MenSCs exerted contrasting impacts
on cell proliferation in MLR (7). Notably, similar
dose-dependent immunomodulatory impacts have
been reported for other MSCs (11, 12). We have
also provided compelling data demonstrating that
MenSCs inhibited optimal maturation of monocyte-
derived dendritic cells (DCs) (13). Despite the
very limited data on MenSC immunomodulatory
impacts, they have been used to treat several
immune-mediated disease models probably due
to their similarities to the well-known MSCs
(14, 15). Furthermore, several studies have
compared the immunomodulatory features and
therapeutic potential of MenSCs and MSCs. In
particular, a recent study reported the lower
immunosuppressive ability of MenSCs versus
BM-MSCs; while MenSCs exerted no beneficial
impacts in the experimental arthritis model, they
were of a potential clinical use in a GVHD model
(16).
Given the aforementioned advantages
and no tumorigenicity and ethical issues
associated with their medical applications,
MenSCs could be viewed as potential tools
besides typical MSCs for utilization in clinical
settings (17). Nevertheless, there is a need to
unravel the detailed mechanisms underlying the
interaction between MenSCs and immune system
cells.
Hence, this study explores whether or not
the change in MenSCs number can affect
the proliferation rate, cytokine level, and
Treg frequency among PBMCs. Furthermore,
considering the large fluctuations in IFN-γ
concentration at different MenSCs-PBMCs
ratios, the potential impact of this cytokine on
the expression of human leukocyte antigen
(HLA)-DR, HLA-ABC, HLA-G and co-stimulatory
molecules by MenSCs was assessed. Information
regarding the pattern, based on which the
level of the aforementioned factors would
fluctuate under various MenSCs concentrations,
would pave the way for the establishment of
improved and to-the-point MenSC inoculation
strategies in the case of future pre-clinical disease
models.
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2. Materials and Methods
2.1. Sample collection
In this in vitro experimental study, MB
specimens were collected from six apparently
healthy individuals. All participants had normal
menstrual cycles, with no history of vaginal
infection three month prior to sample collection,
were at reproductive age (20-40 yr old), had not
received GnRH agonist or hormones for at least
three months before sampling, and had no history
of autoimmune diseases and/or malignancies.
Donor enrolment was carried between 2016 and
2018 at the Avicenna Fertility Center (Tehran,
Iran).
2.2. Antibodies
FITC-conjugated monoclonal antibodies against
CD80 and HLA-DR, as well as PE-conjugated
monoclonal antibodies against CD86, CD40,
CD45, and HLA-ABC were purchased from
BD biosciences (San Jose, CA, USA). PE-
conjugated anti-HLA-G antibody was purchased
from Abcam (USA). Human Regulatory T Cell
Staining Kit #3 (eBiosciences, USA) was used for
detecting CD4, CD25, FOXP3 positive cells (Table
I).
2.3. Co-culture of MenSCs with
allogeneic peripheral blood
mononuclear cells (PBMCs)
The isolation of MenSCs and confirmation of
their functional and immunophenotypic capacities
were all carried out as per our previously
published reports (8, 9). To assess the effect
of MenSCs on proliferation of allogeneic PBMCs
and regulatory T cells and cytokine secretion,
an allogeneic MLR system was planned. PBMCs
isolation was performed using Ficoll-Paque
(Sigma, USA) density gradient centrifugation.
MenSCs from passages two to four were treated
with proliferation inhibitor, mitomycin C (Sigma,
USA), and subsequently seeded in triplicate at
various cell numbers beginning with 1 × 105
cells/well of a 96-well flat-bottomed plate. Six
hours later, allogeneic MLR was set up on MenSCs
culture by adding 2 × 105 PBMCs from two
allogenic individuals. Culture was continued for
three days in RPMI-1640 medium supplemented
with 10% FBS and non-essential amino acids.
In all experiments, the PBMCs were obtained
from fixed two apparently normal volunteers
(8). In order to examine the effect of cell-cell
contact on Treg generation, an allogeneic
MLR-MenSCs co-culture on transwell (0.4 µm
pore size) culture system (Corning, New York,
USA) was also set up. First, 2 × 105 MenSCs
were seeded into the lower chambers of 24
well transwell plates with RPMI-1640 and 10%
FBS. Next, allogeneic PBMCs were loaded
into the upper chambers (2 × 105 from each
individual/well). As the control group, allogeneic
PBMCs were cultured in the absence of MenSCs
(18).
2.4. PBMCs proliferation assay
The MenSCs-mediated modulation of T cell
proliferation in MLR system was assessed
using 3H-thymidine incorporation. MenSCs
were co-cultured with two populations of
allogenic PBMCs for three days in a 5%
CO2, humidified incubator. One micro Curie
of 3H-thymidine (Amersham, Sweden) was
subsequently added to each well with the
incubation continuing for 18 hr. Proliferation
was counted using a liquid scintillation
counter (Wallac 1410, Pharmacia, Sweden)
and results were reported as the mean of
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counts per minute (cpm) for each triplicate
wells of the culture. As the control negative
group, allogeneic PBMCs were cultured in
the absence of MenSCs (named MLR cultures)
(8).
2.5. Analysis of CD4/CD25/FOXP3+
cells
PBMCs were cultured with MenSCs both cell-
cell contact and transwell modes for 72 hr as
described in the previous section. Thereafter,
PBMCs were harvested from the co-culture and
stained using eBioscienceTM Human Regulatory
T Cell Staining Kit #3 for Treg detection as per
manufacturer direction. In brief, the cells were
labeled with CD4-FITC and CD25-PE or their
isotype-matched control antibodies, washed using
stain buffer (PBS with 2% fetal bovine serum
[FBS]), fixed, permeabilized, and finally stained
intra-cellularly with either PE.Cy5-conjugated
anti-human FOXP3 Ab, or its isotype control
Ab according to the manufacturer’s instructions.
Staining was measured using a Partec PAS III
flow cytometer (Münster, Germany) and data were
analyzed and prepared using the FlowJo software
(version 7.6.1.). Tomeasure the percentage of Tregs,
CD4+ cells were selected in the lymphocytes gate.
Then, CD25+FOXP3+ cells were measured among
the CD4+ cells (8).
2.6. Detection of HLA-DR expression
on MenSCs
Our previous results showed that MenSCs
could suppress or support proliferation of PBMCs
depending on MenSCs: PBMCs ratio (7). To
explore the molecular mechanism behind this
phenomenon, we used flow cytometry to explore
the expression of HLA-DR on MenSCs added to
allogeneic MLR system at low and high MenSC
numbers. Cells were then harvested, washed
in cold stain buffer, and incubated for 30 min
in stain buffer containing FITC-HLA-DR and PE-
CD45 antibodies. Afterward, cells were analyzed
using a PAS III flow cytometer. Anti-CD45 was
used to exclude PBMCs from HLA-DR analysis on
MenSCs.
2.7. Cytokine assay
Supernatants of the MenSCs/PBMCs co-
cultures were collected after 72 hr and examined
for the concentration of IFN-γ, IL-10, IL-6, IL-8,
TNF-α, and IL-17A by sandwich ELISA using
commercially available ELISA kits. All kits
were purchased from BD (USA) except IL-17A
ELISA kit which was from eBiosciences (USA).
The minimal detection limits of the aforesaid
cytokines were 4.7, 7.8, 3.1, 3.1, 7.8, and 7.8 pg/ml
respectively.
2.8. Treatment of MenSCs with IFN-𝛾
IFN-γ is one of the key cytokines involved
in the modulation of immune responses. Indeed,
we observed that in MenSCs/PBMCs co-cultures,
the level of IFN-γ fluctuated in parallel with
lymphocyte proliferation, Treg frequency, and HLA-
DR expression. Thus, we sought to determine how
the expression of major histocompatibility complex
(MHC) and co-stimulatory molecules is affected
by IFN-γ treatment. To this end, MenSCs were
cultured without or with different concentrations
of IFN-γ (BD, USA) ranging from 0.1 to 100
U/mL. The expression of HLA-DR, HLA-ABC,
HLA-G, CD80, CD86, and CD40 was assessed
by flow cytometry (19). In all flow cytometric
experiments, the isotype-matched Abs were used
to check for potential non-specific bindings (Table
I).
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Table I. Antibodies used for MenSC staining
Antibody name Clone μL of antibody/100 μL of
staining buffer
Company Cat #
PE mouse anti-human CD40 5C3 20 BD 555589
PE mouse anti-human CD45 HI30 10 BD 555483
FITC mouse anti-human CD80 L307.4 20 BD 557226
PE mouse anti-human CD86 2331 (FUN-1) 20 BD 560957
PE mouse anti-human HLA-ABC EMR8-5 5 BD 565291
FITC mouse anti-human HLA-DR L243 10 BD 347403
PE mouse anti-HLA-G antibody MEM-G/9 1 Abcam ab24384
CD: Cluster of Differentiation, HLA: Human Leukocyte Antigen
2.9. Ethical considerations
Informed written consent was obtained from
all participants before enrolling in this study. The
study was approved by the Institutional Review
Board and the Ethics Committee for Medical
Research of Avicenna Research Institute (code:
88/592).
2.10. Statistical analysis
Statistical comparisons were carried out
via non-parametric Mann-Whitney test in
GraphPad Prism version 5.0.4 for Windows,
GraphPad Software, La Jolla California USA,
www.graphpad.com, and data are expressed
as median with range. In each section, data have
been obtained from five independent experiments.
P-values < 0.05 were considered as statistically
significant.
3. Results
3.1. MenSCs differentially affected
lymphocyte proliferation depending
on co-culture ratio
MenSCs at different ratios were added to
a two-way allogeneic MLR culture system, and
proliferation of PBMCs was then assessed through
3H thymidine incorporation. Accordingly, MenSCs
significantly suppressed allogenic proliferation at
the 1:4 ratio (MenSCs: PBMCs) compared to and
the control group (without MenSCs) (p = 0.02).
In contrast, at lower MenSCs numbers (1:16,
1:32, and 1:64 ratios), proliferation of PBMCs in
allogeneic MLR system was significantly increased
compared to control wells (p = 0.02) (Figure
1A).
3.2. MenSCs-induced regulatory T
cells expansion through cell contact-
dependent mechanisms
To investigate the Treg expansion by MenSCs,
allogeneic PBMCs were co-cultured with MenSCs
in either cell-cell contact or transwell culture
systems for 72 hr. Thereafter, the T cells were
analyzed for the expression of Treg markers using
flow cytometry (Figure 1Ba). Our results showed
that in the presence of cell-cell contact, the
percentage of Tregs was decreased at 1:4 MenSCs-
PBMCs ratio (p = 0.02); while at 1:16 to 1:64 ratios
(lower MenSC numbers), the Treg population was
significantly expanded (p = 0.03) (Figure 1Bb). On
the contrary, in the transwell system (no cell-cell
contact), MenSCs could not affect the percentage
of Tregs (Figure 1C).
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3.3. MenSCs-modulated pro- and anti-
inflammatory cytokine production in a
dose-dependent manner
The impact of different numbers of MenSCs
on the levels of IFN-γ, IL-10, IL-6, IL-8, IL-17, and
TNF-α in two-way allogeneic MLR system was
also investigated. To the results, IFN-γ, IL-17, IL-
10, IL-6, and IL-8 level was significantly higher in
the supernatant of MenSCs/PBMCs co-cultures in
comparison to wells containing allogeneic PBMCs
without MenSCs (control group) (p < 0.05-0.01).
The TNF-α concentration was significantly lower
at 1:4 (p = 0.001) and 1:16 (p = 0.02) ratios in the
supernatant of MenSCs-PBMCs co-cultures. The
number of MenSCs added to co-cultures positively
correlated with its inhibitory impact on TNF-α
production. Notably, lower numbers of MenSCs
induced higher secretion of IFN-γ and IL-17, while
it caused lower production of IL-10, IL-6, and IL-8
(Figure 2, Table II).
3.4. IFN-𝛾-induced HLA-DR expression
on MenSCs
Previous studies have shown that MenSCs
express HLA-ABC molecules but do not express
HLA-DR at steady state (6). Hence, we next
examined whether there is a relationship between
IFN-γ and HLA-DR expression on MenSCs at
different MenSCs-PBMCs ratios. With a decrease
in the number of MenSCs in the co-cultures,
both IFN-γ concentration and HLA-DR expression
on MenSCs increased significantly (Figure 3). To
further examine the impact of IFN-γ on HLA-DR
expression on MenSCs, we treated MenSCs alone
with varying concentrations of exogenous IFN-γ
and compared the results with the steady state
condition (no IFN-γ treatment). Nearly all MenSCs
constitutively expressed HLA-ABC that was not
affected by IFN-γ treatment (Figure 4A). However,
HLA-DR that was only expressed by a minority of
MenSCs at steady state showed a considerable
upregulation with increasing IFN-γ concentration
(p = 0.001) (Figure 4B). Furthermore, we found that
MenSCs did not express co-stimulatory molecules,
CD40 and CD80, but expressed moderate levels
of CD86 (45%) at the steady state condition
(Figure 4C). Importantly, there were no significant
changes in the expression of CD40, CD80, and
CD86 by MenSCs after treatment with different
concentrations of IFN-γ. In addition, about 60% of
MenSCs expressed HLA-G and activation with IFN-
γ exerted no significant impacts on the expression
level of this marker (Figure 4D).
Table II. Cytokine concentration at various MenSC: PBMC ratios
Cytokine MenSC: PBMC ratio
NC* 1:4 1:16 1:32 1:64
IL-6 1629 (331) 73976 (10042) 12077 (24884) 5028 (13690) 2980 (3354)
IL-8 47538 (2931) 777920 (410356) 336060 (324032) 311896 (393031) 203346 (170151)
IL-10 615 (231.6) 1432 (487) 481 (660.6) 333.3 (869) 269.3 (157.6)
IL-17 61.7 (9.7) 197.5 (163.1) 232 (249) 381 (222) 331.9 (66.2)
IFN-𝛾 5444 (3009) 15520 (17131) 33917 (27400) 18944 (29236) 11117 (20962)
TNF-𝛼 3264 (625) 1839 (135) 1667 (643) 136.6 (74.6) -
*Data are presented as median (interquartile range)
MenSC: Menstrual blood-derived stromal/stem cells; PBMC: peripheral blood mononuclear cells; NC: Negative control
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Figure 1. Impact of MenSCs on allogeneic MLR. Two allogeneic PBMCs were co-cultured in the presence of a third-party MenSCs
at different ratios for three days and cell proliferation was measured by 3H-thymidine incorporation (A). Also, the percentage of
Tregs was measured using flow cytometry; CD4+ cells were first gated in lymphocytes and then the percentage of CD25+FoxP3+
cells among CD4+ cells was measured (Ba) and compared between groups (Bb). The same culture system was also set up in a
transwell culture plates with MenSCs and the two allogeneic PBMCs were seeded in the upper and lower chambers and Treg
frequency was assessed as above (C). CPM: Count per minute; NC: Negative control (allogeneic MLR in the absence of MenSCs).
P-values <0.05 are shown with*.
Figure 2. Effect of MenSCs on cytokine secretion in allogeneic MLR. Two allogeneic PBMCs were co-cultured in the presence of
a third-party MenSCs at different ratios. After three days, the concentration of IFN-γ, IL-10, IL-6, IL-8, IL-17, and TNF-α was assessed
in the supernatant using ELISA. NC: Negative control (allogeneic MLR without MenSCs). P-values < 0.05, 0.01, 0.001 are shown
with *, **, and ***, respectively.
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Figure 3. Evaluation of HLA-DR expression on MenSCs and IFN-γ production in the MenSCs/PBMCs co-culture. MenSCs were co-
cultured with allogeneic PBMCs at two different ratios for three days. The expression of HLA-DR on CD45 negative cells (MenSCs)
(A) and IFN-γ concentration in the cell culture supernatant was assessed by flow cytometry and ELISA (B), respectively. (C) Flow
cytometry plots of a representative experiment regarding HLA-DR percentage on MenSCs. P-values < 0.05, and 0.01 are shown
with *, and **, respectively.
Figure 4. Effect IFN-γ treatment on HLA-ABC, HLA-DR, CD86, and HLA-G expression by MenSCs. MenSCs were treated with
different concentrations of IFN-γ for two days and surface expression of themarkers was assessed by flow cytometry. NC: Negative
control (no IFN-γ treatment). P-values < 0.01 and 0.0001 are shown with **, and ****, respectively.
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4. Discussion
In the present study, we report novel aspects of
MenSCs immunomodulatory mode of action. We
had previously shown that the impact of MenSCs
on PBMC proliferation could either be inhibitory or
stimulatory depending on the MenSCs’ number (7).
Besides the injection route, injection interval, the
nature of the disease model, and the source from
which a type of MSC is obtained, one must also
consider another key factor, that is, the number
of injected cells. One of the preliminary steps
in this respect is the establishment of set of in
vitro co-cultures at different cell ratios between
the cells being injected and its most probable
target in the recipient; this might suggest some
points regarding the potential impacts that the
injected cell could exert as well as the underlying
involved mechanisms (16, 18). Such results can
further help the researcher to narrow down their
choices regarding such considerations as the
most efficient cell number to be injected and the
injection intervals and finally spare a considerable
amount of time, expense, and most importantly
number of animals. Indeed, similar strategies
have been used in the case of MSC usage for
GVHD therapy as well as MenSC utilization for
the treatment of two disease models (16, 18).
Needless to say, the subsequent clinical steps
would in part, if not thoroughly, be backed by
data obtained from those preliminary in vitro
studies. Accordingly, in this study, we have shown
that there is a relationship between varying
numbers of MenSCs in co-culture with PBMC and
the concentration of several immunomodulatory
cytokines, as well as the expression of co-
stimulatory markers. This aspect has been
addressed by two previously independent studies.
In one study, the immunosuppressive capabilities
of MenSCs and BM-MSCs in MLR system were
investigated and compared.
Accordingly, when responder T cells were
stimulated in the presence either MenSCs
or BM-MSCs at a concentration of 10,000
cells per well, the BM-MSC were generally
more immunosuppressive. However, at the
concentration of 100,000 cells per well, MenSCs
were significantly more immunosuppressive (20).
The same trend was also reported in another study
where MenSCs showed a similar suppressive
impact on the proliferation of T cells at the 1:10
ratio in comparison with BM-MSCs. However,
in contrast to BM-MSCs that maintained their
inhibitory potential at a higher ratio (1:100), MenSCs
had a stimulatory effect on T cell proliferation
at higher ratios (16). Some other studies have
shown the same trend for allogeneic PBMCs
proliferation mediated by MSCs. Accordingly,
Najar and colleagues showed that bone marrow-
derived MSCs are able to either support or
suppress T cell proliferation at low- and high
densities, respectively. They proposed IL-6 as
the key player responsible for the increase of
T cell proliferation at lower densities of MSCs
(11). In another study conducted by Fang and
co-workers higher proliferative capacity of PBMCs
in the presence of lower density of human MSCs
was linked to increased levels of IL-2 and IFN-γ
resulting in the MHC-II upregulation on MSCs (12).
Similarly, our results showed that augmented T
cell proliferation mediated by lower density of
MenSCs is accompanied by higher concentrations
of IFN-γ and a significant upregulation of HLA-DR
on MenSCs. It is noteworthy that the enhanced
PBMCs proliferation at lower MenSCs densities
could not solely attributed to a few cytokines as the
interaction of MenSCs with the cells of the immune
system potentially results in the production of a
vast array of cytokines and mediators with either
contrasting or synergizing impacts. For instance,
at higher MenSCs densities (numbers), where
proliferation of PBMCs was inhibited, we found
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increased levels of IL-6 which is known to promote
T cell proliferation (21), however, at the same
time, levels of IL-10 was also increased which could
inhibit proliferation of activated T cells (22). Indeed,
it has been reported that IL-6 produced by human
MSCs is, at least in part, responsible for the shift of
M0 macrophages into IL-10-producing cells in vitro
(23).
To our results, there was a positive correlation
between MenSCs seeding density and the
concentration of IL-6, implying the possible role of
IL-6 in modulation of PBMC proliferative response.
Our previous results also showed that MenSCs
could efficiently prevent DCs from fulfilling their
phenotypic maturation which was accompanied
by high levels of IL-6 and IL-10 production (13).
Furthermore, decreased levels of TNF-α and
lower lymphocyte proliferation were detected in
the presence of higher MenSC numbers. It has
been shown that human MSCs caused mature
DCs type 1 (DC1) to decrease TNF-α secretion
and mature DC2 to increase IL-10 secretion (24).
Moreover, quite convincing data published recently
showed that IL-6, besides its pro-inflammatory role,
could function as an anti-inflammatory cytokine
through suppression of the secretion of many
pro-inflammatory cytokines, such as IL-1, TNFα,
GM-CSF, and IFNγ (25). We also observed MenSCs
could increase the production of IL-17, which has
also been reported for other sources of MSCs
including those isolated from synovium and fetal
bone marrow (26, 27).
Considering the opposite impacts of varying
densities of MenSCs on the production of
cytokines, we concluded that MenSCs could
either promote or inhibit the production of pro- or
anti-inflammatory responses depending on their
relative density. MSCs have been reported to
exert antigen-presenting activities under the tight
control of IFN-γ. Such activity is accompanied by
high expression level of MHC-II (19). In this regard,
Desai and colleagues showed that MSCs caused a
significant increase in the proliferation of antigen-
challenged lymphocytes from allergic rhinitis
subjects. They revealed that this correlated with
increased production of inflammatory cytokines
from T cells and increased expression of MHC-
II and CD86 on MSCs (28). Our finding on
the dual impact of MenSCs on lymphocyte
proliferation could be explained, in part, by the
dose-dependent modulation of APC function by
MenSCs.
To further unravel the mechanisms responsible
for the lymphocyte proliferation fluctuation in
different MenSCs densities, the percentage of
Treg cells was examined. Our results showed
that during the 72-hr cell culture period, the
relative frequency of Tregs was not changed
in different MenSCs: PBMCs ratios indicating
that changes in proliferation of PBMCs were
independent of Tregs frequency. In fact, one of
the reasons could be that to observe changes
in Treg frequency, we might need culture times
longer than 72 hr. Furthermore, we found that cell-
cell contact is indispensable for Tregs expansion
in the presence of MenSCs; this suggests that the
production of the soluble factors needed for Treg
expansion depends on the direct contact between
the effector cells and MenSCs. In fact, several
studies have shown that BM-MSCs cultured with
stimulated PBMCs can induce the expansion of
functional CD4+CD25highFOXP3+ Tregs (29, 30).
Other sources of MSCs including those derived
from human placenta and umbilical cord exhibited
the same promoting action on Tregs (31, 32). A
number of mechanisms have been suggested,
both cell-contact-dependent and -independent
mechanisms, however, there is no clear consensus
as of yet.
The increased percentage of
CD4+CD25+FOXP3+ Tregs and levels of pro-
inflammatory cytokine at lower MenSC might
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indicate that Tregs are in part responsible for
production of such cytokines. In this regard, it
has been reported that during their activation
in the presence of appropriate inflammatory
stimuli in vitro, both human and murine Treg
cells display an IL17+FOXP3+CD4+ phenotype
and can produce IL-17 (33, 34). Preclinical studies
also have demonstrated that the therapeutic
effect of MenSCs on the course of experimental
murine colitis is associated with significantly
higher level of CD4+CD25+FOXP3+ Treg cells
(15). In parallel, we showed that pretreatment of
MenSCs with IFN-γ resulted in an upregulation of
HLA-DR in a dose-dependent manner, a finding
that had been reported earlier for BM-MSCs (19).
Therefore, we hypothesize that by decreasing
the MenSC density (number), it is the higher
IFN-γ concentration and consequently higher
HLA-DR expression that is, in part, responsible
for higher proliferation of PBMCs. In line with
this notion, it has been recently reported that the
lower suppressive activity of MenSCs compared to
BM-MSCs is associated with a significantly lower
expression level of IFN-γ receptor-1 and -2 (16).
Therefore, it seems that in contrast to BM-MSCs,
the initiation of immunosuppressive machinery
by MenSCs does not rely mainly on the IFN-γ
signaling pathway. Interestingly, HLA-G protein
expression on MenSCs was constitutive and the
level did not alter in the presence of IFN-γ. In this
regard, a study by Nasef and colleagues showed
that MSCs constitutively express HLA-G, the
level of which is not modified upon stimulation by
allogeneic lymphocytes in the MSC/MLR co-culture
(35).
5. Conclusion
MenSCs can collectively modulate immune
responses; however, MenSCs number and
consequently the dominant microenvironment
components play key roles in presenting
MenSCs as immune suppressor or enhancer
cells. Therefore, we suggest that the researcher
consider these variables while investigating
MenSCs impacts on immune responses in vitro or
preclinical settings.
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